BioWorld

Nov. 30, 2006

Cancer Drug Has Promise In Kidney Disease, Arthritis

Targeted Genetics' Share Price, Volume Jump Go Unexplained

Other News To Note

Clinic Roundup

Hepatitis B Results Provide Boost To Dynavax's Stock

Shares in Dynavax Technologies Corp. soared 32 percent Wednesday on positive Phase III data for its hepatitis B vaccine, Heplisav. (BioWorld Today) Read More

Kalypsys Delving Deeper Into Pipeline With $100M Series C

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...